[A23-130] Zanubrutinib (follicular lymphoma) – Benefit assessment according to §35a Social Code Book V
Last updated 15.03.2024
Project no.:
A23-130
Commission:
Commission awarded on 15.12.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adult patients with refractory or relapsed follicular lymphoma who have received at least 2 prior systemic therapies
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A23-130_en
| Project no. | Title | Status |
|---|---|---|
| A22-132 | Zanubrutinib (chronic lymphocytic leukaemia, relapsed/refractory) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-131 | Zanubrutinib (marginal zone lymphoma) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-130 | Zanubrutinib (chronic lymphocytic leukaemia, first line) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-169 | Zanubrutinib (Waldenström macroglobulinaemia) - Benefit assessment according to §35a Social Code Book V | Commission completed |